CD40 agonist mitazalimab in combination with chemotherapy
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Trial Timeline
Sep 17, 2021 → Jun 30, 2026
NCT ID
NCT04888312About CD40 agonist mitazalimab in combination with chemotherapy
CD40 agonist mitazalimab in combination with chemotherapy is a phase 1/2 stage product being developed by Alligator Bioscience AB for Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04888312. Target conditions include Metastatic Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Ductal Adenocarcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04888312 | Phase 1/2 | Active |
Competing Products
20 competing products in Metastatic Pancreatic Ductal Adenocarcinoma